{"id":44994,"date":"2022-06-13T12:01:40","date_gmt":"2022-06-13T10:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/"},"modified":"2022-06-13T12:01:40","modified_gmt":"2022-06-13T10:01:40","slug":"global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/","title":{"rendered":"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World&#8217;s Pharma and Biotechnology Companies &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/2417905\/global_orphan_diseases_partnering_20102022_deal?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=kt4f2p&amp;utm_campaign=1712500+-+Global+Orphan+Diseases+Partnering+2010-2022%3A+Deal+Trends%2C+Players+and+Financials+for+280+Deals+Signed+Between+the+World%27s+Pharma+and+Biotechnology+Companies&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220613005434\/en\/1484243\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220613005434\/en\/1484243\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe Global Orphan Diseases Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 280 orphan diseases deals signed between the world&#8217;s pharmaceutical and biotechnology companies since 2010.\n<\/p>\n<ul>\n<li>\nTrends in Orphan Diseases partnering deals\n<\/li>\n<li>\nFinancial deal terms for headline, upfront and royalty by stage of development\n<\/li>\n<li>\nOrphan Diseases partnering agreement structure\n<\/li>\n<li>\nOrphan Diseases partnering contract documents\n<\/li>\n<li>\nTop Orphan Diseases deals by value\n<\/li>\n<li>\nMost active Orphan Diseases dealmakers\n<\/li>\n<\/ul>\n<p>\nMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor&#8217;s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&amp;D and a commercialization of outcomes element.\n<\/p>\n<p>\nThe report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.\n<\/p>\n<p>\nThe report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.\n<\/p>\n<p>\nThe initial chapters of this report provide an orientation of Orphan Diseases dealmaking trends.\n<\/p>\n<p>\nChapter 2 provides an overview of the trends in Orphan Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.\n<\/p>\n<p>\nChapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.\n<\/p>\n<p>\nChapter 4 provides a review of the leading Orphan Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Orphan Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.\n<\/p>\n<p>\nChapter 5 provides comprehensive access to Orphan Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.\n<\/p>\n<p>\nChapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2010. The chapter is organized by specific Orphan Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\n<\/p>\n<p>\nIn addition, a comprehensive appendix is provided with each report of all Orphan Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&amp;D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\n<\/p>\n<p>\nThe report also includes numerous tables and figures that illustrate the trends and activities in Orphan Diseases partnering and dealmaking since 2010.\n<\/p>\n<p>\nIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Orphan Diseases technologies and products.\n<\/p>\n<p>\n<strong>Report scope<\/strong>\n<\/p>\n<p>\n<strong>Global Orphan Diseases Partnering 2010 to 2022 includes:<\/strong>\n<\/p>\n<ul>\n<li>\nTrends in Orphan Diseases dealmaking in the biopharma industry since 2010\n<\/li>\n<li>\nAccess to headline, upfront, milestone and royalty data\n<\/li>\n<li>\nAccess to hundreds of Orphan Diseases deal contract documents\n<\/li>\n<li>\nComprehensive access to over 280 Orphan Diseases deal records\n<\/li>\n<li>\nThe leading Orphan Diseases deals by value since 2010\n<\/li>\n<li>\nMost active Orphan Diseases dealmakers since 2010\n<\/li>\n<\/ul>\n<p>\n<strong>In Global Orphan Diseases Partnering 2010 to 2022, available deals and contracts are listed by:<\/strong>\n<\/p>\n<ul>\n<li>\nHeadline value\n<\/li>\n<li>\nUpfront payment value\n<\/li>\n<li>\nRoyalty rate value\n<\/li>\n<li>\nStage of development at signing\n<\/li>\n<li>\nDeal component type\n<\/li>\n<li>\nTechnology type\n<\/li>\n<li>\nSpecific therapy indication\n<\/li>\n<\/ul>\n<p>\n<strong>Analyzing actual contract agreements allows assessment of the following:<\/strong>\n<\/p>\n<ul>\n<li>\nWhat are the precise rights granted or optioned?\n<\/li>\n<li>\nWhat is actually granted by the agreement to the partner company?\n<\/li>\n<li>\nWhat exclusivity is granted?\n<\/li>\n<li>\nWhat is the payment structure for the deal?\n<\/li>\n<li>\nHow are sales and payments audited?\n<\/li>\n<li>\nWhat is the deal term?\n<\/li>\n<li>\nHow are the key terms of the agreement defined?\n<\/li>\n<li>\nHow are IPRs handled and owned?\n<\/li>\n<li>\nWho is responsible for commercialization?\n<\/li>\n<li>\nWho is responsible for development, supply, and manufacture?\n<\/li>\n<li>\nHow is confidentiality and publication managed?\n<\/li>\n<li>\nHow are disputes to be resolved?\n<\/li>\n<li>\nUnder what conditions can the deal be terminated?\n<\/li>\n<li>\nWhat happens when there is a change of ownership?\n<\/li>\n<li>\nWhat sublicensing and subcontracting provisions have been agreed?\n<\/li>\n<li>\nWhich boilerplate clauses does the company insist upon?\n<\/li>\n<li>\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\n<\/li>\n<li>\nWhich jurisdiction does the company insist upon for agreement law?\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>Executive Summary<\/strong>\n<\/p>\n<p>\n<strong>Chapter 1 &#8211; Introduction<\/strong>\n<\/p>\n<p>\n<strong>Chapter 2 &#8211; Trends in Orphan Diseases dealmaking<\/strong>\n<\/p>\n<p>\n2.1. Introduction\n<\/p>\n<p>\n2.2. Orphan Diseases partnering over the years\n<\/p>\n<p>\n2.3. Orphan Diseases partnering by deal type\n<\/p>\n<p>\n2.4. Orphan Diseases partnering by industry sector\n<\/p>\n<p>\n2.5. Orphan Diseases partnering by stage of development\n<\/p>\n<p>\n2.6. Orphan Diseases partnering by technology type\n<\/p>\n<p>\n<strong>Chapter 3 -Financial deal terms for Orphan Diseases partnering<\/strong>\n<\/p>\n<p>\n3.1. Introduction\n<\/p>\n<p>\n3.2. Disclosed financials terms for Orphan Diseases partnering\n<\/p>\n<p>\n3.3. Orphan Diseases partnering headline values\n<\/p>\n<p>\n3.4. Orphan Diseases deal upfront payments\n<\/p>\n<p>\n3.5. Orphan Diseases deal milestone payments\n<\/p>\n<p>\n3.6. Orphan Diseases royalty rates\n<\/p>\n<p>\n<strong>Chapter 4 &#8211; Leading Orphan Diseases deals and dealmakers<\/strong>\n<\/p>\n<p>\n4.1. Introduction\n<\/p>\n<p>\n4.2. Most active in Orphan Diseases partnering\n<\/p>\n<p>\n4.3. List of most active dealmakers in Orphan Diseases\n<\/p>\n<p>\n4.4. Top Orphan Diseases deals by value\n<\/p>\n<p>\n<strong>Chapter 5 &#8211; Orphan Diseases contract document directory<\/strong>\n<\/p>\n<p>\n5.1. Introduction\n<\/p>\n<p>\n5.2. Orphan Diseases partnering deals where contract document available\n<\/p>\n<p>\n<strong>Chapter 6 &#8211; Orphan Diseases dealmaking by therapeutic target<\/strong>\n<\/p>\n<p>\n6.1. Introduction\n<\/p>\n<p>\n6.2. Deals by Orphan Diseases therapeutic target\n<\/p>\n<p>\n<strong>Appendices<\/strong>\n<\/p>\n<p>\nAppendix 1 &#8211; Directory of Orphan Diseases deals by company A-Z since 2010\n<\/p>\n<p>\nAppendix 2 &#8211; Directory of Orphan Diseases deals by deal type since 2010\n<\/p>\n<p>\nAppendix 3 &#8211; Directory of Orphan Diseases deals by stage of development since 2010\n<\/p>\n<p>\nAppendix 4 &#8211; Directory of Orphan Diseases deals by technology type since 2010\n<\/p>\n<p>\n<strong>Table of figures<\/strong>\n<\/p>\n<p>\nFigure 1: Orphan Diseases partnering since 2010\n<\/p>\n<p>\nFigure 2: Orphan Diseases partnering by deal type since 2010\n<\/p>\n<p>\nFigure 3: Orphan Diseases partnering by industry sector since 2010\n<\/p>\n<p>\nFigure 4: Orphan Diseases partnering by stage of development since 2010\n<\/p>\n<p>\nFigure 5: Orphan Diseases partnering by technology type since 2010\n<\/p>\n<p>\nFigure 6: Orphan Diseases partnering by indication since 2010\n<\/p>\n<p>\nFigure 7: Orphan Diseases deals with a headline value\n<\/p>\n<p>\nFigure 8: Orphan Diseases deals with upfront payment values\n<\/p>\n<p>\nFigure 9: Orphan Diseases deals with milestone payment\n<\/p>\n<p>\nFigure 10: Orphan Diseases deals with royalty rates\n<\/p>\n<p>\nFigure 11: Active Orphan Diseases dealmaking activity since 2010\n<\/p>\n<p>\nFigure 12: Top Orphan Diseases deals by value since 2010\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nMSD Action Foundation (MSDAF)\n<\/li>\n<li>\nOxford BioMedica\n<\/li>\n<li>\nEdmond Pharma\n<\/li>\n<li>\nLigand Pharmaceuticals\n<\/li>\n<li>\nFlorida Biologix\n<\/li>\n<li>\nAbbvie\n<\/li>\n<li>\nCastle Creek Pharmaceuticals\n<\/li>\n<li>\nNestle Health Science\n<\/li>\n<li>\nEnable Injections\n<\/li>\n<li>\nBioTie Therapies\n<\/li>\n<li>\nEuropean Commission\n<\/li>\n<li>\nG-treeBNT\n<\/li>\n<li>\nOncoSec Medical\n<\/li>\n<li>\nBioNTech\n<\/li>\n<li>\nHematech\n<\/li>\n<li>\nDBV Technologies\n<\/li>\n<li>\nVideregen\n<\/li>\n<li>\nCSL Behring\n<\/li>\n<li>\nBioXcel\n<\/li>\n<li>\nVericel\n<\/li>\n<li>\nLeukaemia &amp; Lymphoma Research\n<\/li>\n<li>\nArmaGen\n<\/li>\n<li>\nAbiogen Pharma\n<\/li>\n<li>\nJanssen Sciences\n<\/li>\n<li>\nSoligenix\n<\/li>\n<li>\nMedicenna Therapeutics\n<\/li>\n<li>\nCatalent\n<\/li>\n<li>\nCutaneous Lymphoma Foundation\n<\/li>\n<li>\nNovasep\n<\/li>\n<li>\nOncoPep\n<\/li>\n<li>\nMoulder Center for Drug Discovery Research\n<\/li>\n<li>\nSpooner Girls Foundation\n<\/li>\n<li>\nJupiter Orphan Therapeutics\n<\/li>\n<li>\nMarnier-Lapostolle Foundation\n<\/li>\n<li>\nPlexcera\n<\/li>\n<li>\nProThera\n<\/li>\n<li>\nKalytera Therapeutics\n<\/li>\n<li>\nAcceleron Pharma\n<\/li>\n<li>\nRegenerx\n<\/li>\n<li>\nFortress Biotech\n<\/li>\n<li>\nSynageva BioPharma\n<\/li>\n<li>\nImmuneWorks\n<\/li>\n<li>\nRare Expertise\u00a0\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/2417905\/global_orphan_diseases_partnering_20102022_deal?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=kt4f2p&amp;utm_campaign=1712500+-+Global+Orphan+Diseases+Partnering+2010-2022%3A+Deal+Trends%2C+Players+and+Financials+for+280+Deals+Signed+Between+the+World%27s+Pharma+and+Biotechnology+Companies&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/exukox<\/a>\n<\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong>\n<\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;&#111;&#x3a;p&#114;&#x65;s&#x73;&#x40;&#114;&#x65;s&#101;&#x61;r&#x63;&#x68;&#97;&#x6e;d&#109;&#x61;&#114;&#x6b;e&#116;&#x73;&#46;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#101;&#115;s&#x40;&#x72;&#x65;&#115;&#101;a&#x72;&#x63;&#x68;&#97;&#110;d&#x6d;&#x61;&#x72;&#107;&#101;t&#x73;&#x2e;&#x63;&#111;m<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The Global Orphan Diseases Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 280 orphan diseases deals signed between the world&#8217;s pharmaceutical and biotechnology companies since 2010. Trends in Orphan Diseases &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44994","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World&#039;s Pharma and Biotechnology Companies - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World&#039;s Pharma and Biotechnology Companies - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The Global Orphan Diseases Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 280 orphan diseases deals signed between the world&#8217;s pharmaceutical and biotechnology companies since 2010. Trends in Orphan Diseases ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T10:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220613005434\/en\/1484243\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World&#8217;s Pharma and Biotechnology Companies &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-06-13T10:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/\"},\"wordCount\":1286,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005434\\\/en\\\/1484243\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/\",\"name\":\"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World's Pharma and Biotechnology Companies - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005434\\\/en\\\/1484243\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-06-13T10:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005434\\\/en\\\/1484243\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005434\\\/en\\\/1484243\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World&#8217;s Pharma and Biotechnology Companies &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World's Pharma and Biotechnology Companies - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World's Pharma and Biotechnology Companies - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The Global Orphan Diseases Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 280 orphan diseases deals signed between the world&#8217;s pharmaceutical and biotechnology companies since 2010. Trends in Orphan Diseases ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-13T10:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220613005434\/en\/1484243\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World&#8217;s Pharma and Biotechnology Companies &#8211; ResearchAndMarkets.com","datePublished":"2022-06-13T10:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/"},"wordCount":1286,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220613005434\/en\/1484243\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/","name":"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World's Pharma and Biotechnology Companies - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220613005434\/en\/1484243\/21\/logo.jpg","datePublished":"2022-06-13T10:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220613005434\/en\/1484243\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220613005434\/en\/1484243\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-orphan-diseases-partnering-2010-2022-deal-trends-players-and-financials-for-280-deals-signed-between-the-worlds-pharma-and-biotechnology-companies-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials for 280 Deals Signed Between the World&#8217;s Pharma and Biotechnology Companies &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44994"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44994\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}